Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases

Kabir, Ali; Pazouki, Abdolreza; Jafari, Motahareh; Mokhber, Somayye; Vaziri, Mohammad; Alavian, Seyed Moayed

doi:10.18869/acadpub.ibj.21.3.197

Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases

Authors

Ali Kabir ¹

Abdolreza Pazouki ¹

Motahareh Jafari ¹

Somayye Mokhber ¹

Mohammad Vaziri ¹

Seyed Moayed Alavian ²

¹ Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran

² Middle East Liver Disease Center, Tehran, Iran

10.18869/acadpub.ibj.21.3.197

Abstract

Background: There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases. Methods: In this cross-sectional study, 242 obese/overweight and 85 non-obese individuals were participated. Cases were selected from a referral clinic for obesity and a referral hepatology clinic, both in Tehran, Iran.

Results: Obese cases had lower percentage of liver diseases (66.9% vs. 100%, P<0.001) but higher hepatitis B vaccination history (74.9% vs. 51.2%, P<0.001). Median±inter-quartile range of anti-HBs titer in obese cases was significantly lower than controls (48.5±194.5 vs. 100±557.6, P=0.012). Conclusion: The level of anti-HBs surface antigen antibody’s titer in obese cases without liver disease is lower than control group. Therefore, a suitable strategy is needed to overcome this problem, which can be the use of longer needles for vaccination.

Keywords

Hepatitis B Vaccines

Obesity

Liver diseases

Immunosuppressive agent